1
|
Kujawski M, Li L, Li H, Yazaki PJ, Swiderski P, Shively JE. T-cell surface generation of dual bivalent, bispecific T-cell engaging, RNA duplex cross-linked antibodies (dbBiTERs) for re-directed tumor cell lysis. Biotechnol J 2022; 17:e2100389. [PMID: 34773368 PMCID: PMC9177045 DOI: 10.1002/biot.202100389] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 11/06/2021] [Accepted: 11/09/2021] [Indexed: 02/03/2023]
Abstract
BACKGROUND Genetic engineered Bispecific T-cell engagers (BiTEs) generate potent cytotoxic effects. METHODS Alternately, click chemistry engineered, dual specific bivalent Bispecific T-cell engaging antibodies (dbBiTEs) on T-cell surfaces can be generated from parent monoclonal antibodies. RESULTS We show the formation of dbBiTEs on the surface of T-cells along with the introduction of complementary 2'-OMe RNA 32-mer oligonucleotides allowing duplex formation between antibodies, designated as dbBiTERs. dbBiTERs generated in solution from anti-CEA and anti-CD3 OKT3 antibodies retained specific binding to CEA positive versus CEA negative cancer cells and to CD3 positive T-cells comparable to dbBiTEs. When T-cells were precoated with dbBiTEs or dbBiTERs and mixed with CEA positive versus CEA negative cancer cells, similar dose dependent and specific cytotoxicity were observed in redirected cell lysis assays. On-cell generated dbBiTERs exerted potent cytotoxic responses against CEA positive targets and were localized at the cell surface by immuno-gold EM. In addition, we demonstrate that target and T-cells, each coated separately with complementary 2'OMe-RNA-linked antibodies can be cross-linked by RNA duplex formation in vitro to generate redirected cell lysis. CONCLUSION The facile generation of dbBiTERs with specific cytolytic activity from intact antibodies and their generation on-cell offers a new avenue for antigen specific T-cell therapy.
Collapse
Affiliation(s)
- Maciej Kujawski
- Department of Immunology and Theranostics, City of Hope, Duarte, California, USA
| | - Lin Li
- Department of Immunology and Theranostics, City of Hope, Duarte, California, USA
| | - Harry Li
- Department of Immunology and Theranostics, City of Hope, Duarte, California, USA
| | - Paul J. Yazaki
- Department of Immunology and Theranostics, City of Hope, Duarte, California, USA
| | - Piotr Swiderski
- Shared Resources-DNA/RNA/Peptide, City of Hope, Duarte, California, USA
| | - John E. Shively
- Department of Immunology and Theranostics, City of Hope, Duarte, California, USA
| |
Collapse
|
2
|
Gupta VR, Root A, Fisher T, Norberg R, David J, Clark T, Cohen J, May C, Giddabasappa A. Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecific and trafficking of adoptively transferred T cells in mouse xenograft model. Oncotarget 2020; 11:1344-1357. [PMID: 32341754 PMCID: PMC7170501 DOI: 10.18632/oncotarget.27544] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2019] [Accepted: 03/14/2020] [Indexed: 02/06/2023] Open
Abstract
P-cadherin-LP-DART is a bispecific antibody targeting P-cadherin expressed on the tumor cells and CD3 on the T-cells. Previously we demonstrated the development and efficacy of P-cadherin-LP-DART in in vitro and in vivo models. Here, we evaluated the three pillars: exposure, targeting specificity and pharmacodynamic modulation for P-cadherin-LP-DART using fluorescence molecular tomography (FMT). Bispecific antibodies and T-cells were conjugated with a near-infrared fluorophores: VivoTag®680XL (VT680) and CellVue®NIR815 (CV815), respectively. In vitro binding and cytotoxic T-lymphocyte assay demonstrated that P-cadherin-LP-DART significantly retained its properties after VT680 conjugation. In vivo FMT imaging was performed to determine the bispecific biodistribution and T-cell trafficking in HCT-116 xenograft model. Peak tumor exposure (2.71%ID) was observed at 96 hr post-injection with measurable quantity even at 240 hr (1.46%ID) (Pillar 1). P-cadherin-LP-DART accumulation in tumor was 20-25 fold higher compared to Control-LP-DART demonstrating the targeting specificity (Pillar 2). Imaging after engraftment of CV815 labeled T-cells showed P-cadherin-LP-DART mediated T-cell trafficking in tumors (Pillar 3). This study harnessed the multichannel capability of FMT and demonstrated the targeting of drug and trafficking of T cells to tumors, simultaneously. Our results show the impact of molecular imaging in demonstrating three pillars of pharmacology, longitudinally and non-invasively.
Collapse
Affiliation(s)
- Vijay R Gupta
- Global Science & Technology (GST) - Comparative Medicine, Pfizer Global Research Development and Medical, San Diego, CA 92121, USA
| | - Adam Root
- BioMedicine Design, Cambridge, MA 02139, USA
| | - Timothy Fisher
- Oncology Research and Development, San Diego, CA 92121, USA
| | - Rand Norberg
- Global Science & Technology (GST) - Comparative Medicine, Pfizer Global Research Development and Medical, San Diego, CA 92121, USA
| | - John David
- Global Science & Technology (GST) - Comparative Medicine, Pfizer Global Research Development and Medical, San Diego, CA 92121, USA
| | - Tracey Clark
- PDM Biotherapeutics, Pfizer Inc., San Diego, CA 92121, USA
| | | | - Chad May
- Oncology Research and Development, San Diego, CA 92121, USA
| | - Anand Giddabasappa
- Global Science & Technology (GST) - Comparative Medicine, Pfizer Global Research Development and Medical, San Diego, CA 92121, USA
| |
Collapse
|
3
|
Ruan S, Lin M, Zhu Y, Lum L, Thakur A, Jin R, Shao W, Zhang Y, Hu Y, Huang S, Hurt EM, Chang AE, Wicha MS, Li Q. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis. Cancer Res 2019; 80:771-783. [PMID: 31843981 DOI: 10.1158/0008-5472.can-19-1145] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 09/30/2019] [Accepted: 12/10/2019] [Indexed: 12/13/2022]
Abstract
Integrin β4 (ITGB4) has been shown to play an important role in the regulation of cancer stem cells (CSC). Immune targeting of ITGB4 represents a novel approach to target this cell population, with potential clinical benefit. We developed two immunologic strategies to target ITGB4: ITGB4 protein-pulsed dendritic cells (ITGB4-DC) for vaccination and adoptive transfer of anti-CD3/anti-ITGB4 bispecific antibody (ITGB4 BiAb)-armed tumor-draining lymph node T cells. Two immunocompetent mouse models were utilized to assess the efficacy of these immunotherapies in targeting both CSCs and bulk tumor populations: 4T1 mammary tumors and SCC7 head and neck squamous carcinoma cell line. Immunologic targeting of ITGB4 utilizing either ITGB4-DC or ITGB4 BiAb-T cells significantly inhibited local tumor growth and metastases in both the 4T1 and SCC7 tumor models. Furthermore, the efficacy of both of these ITGB4-targeted immunotherapies was significantly enhanced by the addition of anti-PD-L1. Both ITGB4-targeted immunotherapies induced endogenous T-cell cytotoxicity directed at CSCs as well as non-CSCs, which expressed ITGB4, and immune plasma-mediated killing of CSCs. As a result, ITGB4-targeted immunotherapy reduced not only the number of ITGB4high CSCs in residual 4T1 and SCC7 tumors but also their tumor-initiating capacity in secondary mouse implants. In addition, treated mice demonstrated no apparent toxicity. The specificity of these treatments was demonstrated by the lack of effects observed using ITGB4 knockout 4T1 or ITGB4-negative CT26 colon carcinoma cells. Because ITGB4 is expressed by CSCs across a variety of tumor types, these results support immunologic targeting of ITGB4 as a promising therapeutic strategy.Significance: This study identifies a novel mechanism of resistance to anti-PD-1/PD-L1 immunotherapy mediated by HPV E5, which can be exploited using the HPV E5 inhibitor rimantadine to improve outcomes for head and neck cancer patients.
Collapse
Affiliation(s)
- Shasha Ruan
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.,Department of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China
| | - Ming Lin
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Yong Zhu
- Guangzhou Improve Medical Instruments Co., Ltd. Guangzhou, Guangdong, China
| | - Lawrence Lum
- Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, Virginia
| | - Archana Thakur
- Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, Virginia
| | - Runming Jin
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Wenlong Shao
- The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou, China
| | - Yalei Zhang
- The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Institute of Respiratory Health, Guangzhou, China
| | - Yangyang Hu
- Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Shiang Huang
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | | | - Alfred E Chang
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
| | - Max S Wicha
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
| | - Qiao Li
- Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
| |
Collapse
|